By dhara Patel
MDMA, commonly referred to as ecstasy or molly, has dominated American club culture and continues to maintain a presence in modern rave and concert scenes despite its risks as a substance with high potential for addiction and abuse. Formally, 3,4-Methylenedioxymethamphetamine (MDMA) is a synthetically manufactured drug that stimulates the user’s nervous system while simultaneously inducing vivid hallucinations. Particularly appealing to younger audiences, MDMA produces a sense of increased energy and pleasure, along with emotional warmth and contentment; however, its use can simultaneously cause distorted sensations and time perceptions (NIDA, 2020). Additionally, researchers have noted that MDMA sold from street dealers is typically combined with other illicit drugs to amplify the effects people experience, adding to potential health risks.
After extensive testing and research studies, it has been determined that MDMA targets the activity of three specific neurotransmitters: dopamine, norepinephrine, and most importantly, serotonin (NIDA, 2020). MDMA acts as a monoaminergic agonist to the receptors of these neurotransmitters, indicating that it both stimulates release and inhibits reuptake. In turn, a tolerance is built up amongst MDMA abusers, causing recreational doses to reach unsafe levels (Parrott, 2001). Researchers note that, after the initial dose, effects begin appearing 45 minutes later and peak for 15-30 minutes, lasting roughly 3 hours in total, with side effects lasting multiple days (NIDA, 2022). The effects of the initial high include “enhanced sense of well-being, increased extroversion, emotional warmth, empathy towards others, and a willingness to discuss emotionally charged memories,” which can be within 45 minutes of the first dose. However, numerous adverse effects can appear during recreational use as well: most notably, hypertension, faintness, panic attacks, potential loss of consciousness, seizures, and hyperthermia. Less common immediate effects of the drug include “involuntary jaw clenching, lack of appetite, mild detachment from oneself or depersonalization, illogical and disorganized thoughts, restless legs, nausea, hot flashes, chills, headaches, sweating, muscle stiffness, and joint stiffness.” The hours following the peak of the high are characterized by impaired motor skills and changes in perception and prediction of movement (NIDA, 2022). Although the “high” wears off after about 3-6 hours, the user typically experiences lingering side effects in the following hours (NIDA, 2020). Although MDMA has not been determined to be as addictive as substances like cocaine, the link it has to the dopamine receptors in the brain’s reward pathway indicates its potential for addiction (NIDA, 2020). From a neurological perspective, repeated abuse can gradually interfere with the serotonergic and dopaminergic mechanisms and pathways in the brain, fueling addiction to the drug. Additionally, the reported influx of hippocampal glutamate and serotonin concentrations damage the hippocampus, causing a deficit in learning and memory (Mustafa et al., 2020). Common lingering effects include “deficits in learning, memory, higher cognitive processing, sleep, appetite, and psychiatric well-being” (Parrott, 2001).
Initially made for medical purposes, a German pharmaceutical company developed MDMA in 1912 to help control bleeding. Towards the 1970s and 1980s, psychiatrists began to discover the benefits that MDMA had on communication, leading to MDMA becoming widely available and used despite the lack of formal clinical trials and legal approval (NIDA, 2022). Its clinical popularity and known potential as a hallucinogen contributed to widespread availability of MDMA, leading to recreational use proven by “street samples” being found as early as 1970 (Passie, 2016). MDMA has since been banned by the Drug Enforcement Administration (DEA) since 1988; however, there have been various studies exploring the potential benefits of MDMA for patients who suffer from post-traumatic stress disorder and anxiety. According to data gathered from an MDMA-assisted therapy designed for patients with severe PTSD, the CAPS-5 total severity score, SDS total score, and BDI-II score all decreased more among patients with MDMA-assisted therapy than those with the placebo over the course of an 18-week trial (Mitchell et al., 2021). The decreased CAPS-5 total severity scores indicates decreased symptoms of PTSD, the decreased SDS total score indicates a lower level of impairment in completely daily life activities they face due to their PTSD, and decreased BDI-II indicates a decrease in depressive symptoms. This indicates positive primary and secondary outcomes in participants due to loss of diagnosis, lack of long-term remission, and mitigation of depressive symptoms compared to the control group. A different pilot study based on Mitchell’s 2021 trial studies intends to implement MDMA-assisted group therapy amongst U.S. veterans suffering from PTSD as a proposed novel protocol for veterans, offering a unique approach to MDMA-assisted therapy contrasting with traditional one-on-one MDMA-assisted therapy methods (Stauffer et al., 2025). The development of novel protocols proposing additional avenues of MDMA research demonstrates the potential for MDMA in medicine and mental health treatment if allowed by changes in DEA policy.
With a growing number of individuals in the United States abusing MDMA, there is still little incentive for the DEA to lift the ban and allow clinical trials and research studies to resume in the USA. SAMHSA’s 2024 National Survey on Drug Use and Health revealed that the percentage of ecstasy abuse was highest amongst young adults, ages ranging from 18 to 25, with approximately 2.4 million young adults using and abusing MDMA. While using the drug recreationally is not necessarily fatal, data from the Centers for Disease Control states that “nearly 23% of all drug overdose deaths involved psychostimulants,” one of which is ecstasy (Miller, 2023). Although promise for the drug is evident, the number of people who recreationally abuse ecstasy has yet to decline, barring incentive for change on a systemic scale.
Despite the risks, youth and adults alike continue to abuse ecstasy for feelings of pleasure that stem from the neurological changes; however, the lack of regulation regarding psychostimulants and their role in pop culture has created a barrier barring researchers and care providers from accessing a novel form of treatment. Although a lot of information has been gathered surrounding ecstasy and its effects over the past 40 years, there are still many aspects of the drug that evades scientists and medical professionals alike, and many of the long-term dangers are still unknown and need to be researched further; however, despite the drug’s risks and abuse in pop-culture, adequate societal regulation and additional investment in research can unlock the drug’s full potential in clinical settings.
References
Klam, M. (2001, January 21). Experiencing Ecstasy. The New York Times. https://www.nytimes.com/2001/01/21/magazine/experiencing-ecstasy.html
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. & et al. (2021, May 10). MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. https://www.nature.com/articles/s41591-021-01336-3
Mustafa, N. S., & et al. (2020, July 1). “MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity.” Basic and Clinical Neuroscience, 2020, www.ncbi.nlm.nih.gov/pmc/articles/PMC7878040/.
NIDA. (2020, June 15). MDMA (Ecstasy/Molly) DrugFacts. https://nida.nih.gov/publications/drugfacts/mdma-ecstasymolly
NIDA. (2022, December 19). MDMA (Ecstasy) Abuse Research Report. https://nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/Introduction
Parrott AC. (2001, December 16). Human Psychopharmacology of Ecstasy (MDMA): A Review of 15 Years of Empirical Research. https://pubmed.ncbi.nlm.nih.gov/12404536/#full-view-affiliation-1
Passie, Torsten, and Udo Benzenhöfer. “The History of MDMA as an Underground Drug in the United States, 1960-1979.” Journal of psychoactive drugs vol. 48,2 (2016): 67-75. doi:10.1080/02791072.2015.1128580
Stauffer, C.S., & et al. “MDMA-Assisted Group Therapy for PTSD: Development of a Novel Protocol.” Cognitive and Behavioral Practice, vol. 32, no. 3, Aug 2025, pp. 339-350. Science Direct, https://doi.org/10.1016/j.cbpra.2025.03.001.